We are proud to share that our validation study was presented in the Late-Breaking Science section at ESC Heart Failure 2025—the world’s leading conference dedicated to heart failure. This prestigious section is reserved for the most impactful studies of the year, and for the first time ever, a study from Slovakia was featured there.
Our study demonstrates the clinical validity of the Seerlinq® algorithm in assessing left ventricular filling pressure (LVFP) non-invasively and remotely — an achievement that led to our CE MDR Class IIb certification as a medical device.
Watch the full presentation here.